Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 12, 2016, Pages 1311-1318

  Chen, Y C ^a   Jeng, W J ^a   Chien, R N ^a   Chu, C M ^a   Liaw, Y F ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE; VIRUS ANTIBODY;

ADULT; ARTICLE; CASE CONTROL STUDY; CHRONIC HEPATITIS B; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PROPENSITY SCORE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SEPSIS; SEROCONVERSION; SEROLOGY; BLOOD; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, VIRAL; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEOTIDES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84963653830     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13630     Document Type: Article

References (32)

1. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Chu CM, Liaw YF,. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-43.
3. Chen YC, Sheen IS, Chu CM, Liaw YF,. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-9.
4. Yuen MF, Wong DK, Sablon E, et al,. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-701.
5. Ahn SH, Park YN, Park JY, et al,. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42: 188-94.
6. Arase Y, Ikeda K, Suzuki F, et al,. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71.e9-e16.
7. Yuen MF, Wong DK, Fung J, et al,. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
8. Kim GA, Lee HC, Kim MJ, et al,. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 2015; 62: 1092-9.
9. Simonetti J, Bulkow L, McMahon BJ, et al,. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-7.
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
11. Buti M, Tsai N, Petersen J, et al,. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60: 1457-64.
12. Idilman R, Cinar K, Seven G, et al,. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2012; 19: 220-6.
13. Seto WK, Wong DK, Fung J, et al,. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31.
14. Hosaka T, Suzuki F, Kobayashi M, et al,. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol 2013; 48: 930-41.
15. Kim GA, Lim YS, An J, et al,. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2014; 63: 1325-32.
16. Kobayashi M, Hosaka T, Suzuki F, et al,. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol 2014; 49: 538-46.
17. Seto WK, Cheung KS, Wong DK, et al,. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol 2015; doi: 10.1007/s00535-015-1128-2 [Epub ahead of print].
18. Hsu YS, Chien RN, Yeh CT, et al,. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
19. Kuo LF, Lee CM, Hung CH, et al,. High risk of hepatitis B virus reactivation in nucleos(t)e analogue-induced hepatitis B e antigen seroconverters older than 40 years. Dig Dis Sci 2014; 59: 2580-7.
20. Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HL,. Nucleos(t)ide analogues only induce temporary hepatitis B eantigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
21. Fong TL, Tien A, Jo KJ, et al,. Durability of hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with entecavir or tenofovir. Dig Dis Sci 2015; 60: 3465-72.
22. Chu CM, Liaw YF,. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-92.
23. Lin DY, Sheen IS, Chiu CT, et al,. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21: 303-8.
24. Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF,. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015; 42: 1182-91.
25. Liaw YF, Tai DI, Chu CM, et al,. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. Gastroenterology 1986; 90: 263-7.
26. Bruix J, Sherman M,. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
27. Chu CM, Lin DY, Liaw YF,. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci 2013; 58: 275-81.
28. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
29. Terrault NA, Bzowej NH, Chang KM, et al,. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83.
30. Di Bisceglie AM,. Hepatitis B and hepatocellular carcinoma. Hepatology 2009; 49: s56-60.
31. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
32. Kao JH,. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46: 400-7.